Pharmafile Logo

News and Press Releases

SGLT2 HYPE – a guideline-relevant, clinical trial aiming to establish SGLT2 inhibitors as a new standard in hypertension therapy, ultimately addressing one of the leading causes of premature mortality in Germany and Europe

25 March 2025 -- Lübeck, Germany -- On January 1, 2025, the European research project SGLT2 HYPE (SGLT2 inhibition for cardiovascular reduction in HYPErtension) was officially launched, receiving €6.99 million...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025

SGLT2 HYPE
Florian.Riegel@arttic-innovation.de

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activity Tolebrutinib...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD 2025 Conference

Data show positive impact of small molecule GAL-201 on Aβ-induced toxicity, caused by various Aβ isoforms: beneficial effects on synaptic plasticity and neuroinflammation 24 March 2025 -- Maryland, US and...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025

Galimedix Therapeutics
info@galimedix.com
3704 Calvend Lane Kensington, MD 20895 USA

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025

Innovent
pr@innoventbio.com
1 Kingdom Street, Suite 445-446, London, W2 6BD, United Kingdom

HEALEY ALS Platform Trial Preparation Shows Positive Respiratory Outcome of NUZ-001

Updates to HEALEY ALS Platform Trial Master Protocol have been made to enhance the potential of establishing a clinically meaningful outcome for patients, including: Treatment period extended from 24 to...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025

Neurizon Therapeutics
enquiries@neurizon.com
Level 4, 96-100 Albert Road South Melbourne, VIC 3205 Australia

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

First and only EZH2 inhibitor approved by the NMPA HUTCHMED’s fourth product, and its first approval in hematological malignancies. 21 March 2025 -- Hong Kong, Shanghai & New Jersey, US...

Category:
Posted: March 21, 2025

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

FLAMOD against respiratory infections: phase I clinical trial of innovative new drug begins

20 March 2025 -- Lausanne, Switzerland -- A phase I clinical trial for a groundbreaking therapeutic innovation against respiratory infections has begun at the Clinical Investigation Centre of the Academic...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

European Respiratory Society
4, Avenue Ste-Luce CH 1003 Lausanne Switzerland

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 20, 2025

Pharming Group NV
info@pharming.com
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front....

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience with Investment in Click Therapeutics for Digital Therapeutics beyond Clinical Trials

This investment will improve the healthcare experience for patients, reinforcing Dassault Systèmes’ role in the industry’s transformation Click Therapeutics will gain access to Dassault Systèmes’ global presence and expertise to...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: March 19, 2025

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

19 March 2025 -- Hong Kong, Shanghai & New Jersey, US -- HUTCHMED (China) Limited and Innovent Biologics, Inc, today jointly announce that the FRUSICA-2 Phase II/III clinical trial evaluating...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 19, 2025

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

SolasCure enrols first patient in a next Phase II clinical trial to advance Aurase Wound Gel

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers 17 March 2025 -- Cambridge,...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: March 17, 2025

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

Advarra Unveils Oncology Research Pulse

Content-driven program brings together clinical trial stakeholders to foster knowledge sharing and collaboration in cancer research 12 March 2025 -- Maryland, US -- Advarra, the market leader in regulatory review...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 12, 2025

Advarra
6100 Merriweather Dr., Suite 600 Columbia, MD 21044

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

Combination of complete skin clearance data and favourable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (Pso) treated with...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG